Disclosed is a method for producing D-glucuronic acid by means of biological fermentation and a method for preparing glucurolactone using glucuronic acid, which belong to the technical field of biological preparation. The methods comprise the following steps: culturing recombinant engineering bacteria to obtain a seed solution; inoculating the seed solution onto a fermentation tank culture medium for fermentation culture; obtaining a fermentation solution by means of feeding control and induction control; performing centrifugation or membrane filtration on the fermentation solution to obtain a wet thallus; and adding the wet thallus to a reaction solution for conversion to obtain D-glucuronic acid. Furthermore, adding the D-glucuronic acid solution to a concentrated phosphoric acid, performing an esterification reaction under stirring conditions at a reaction temperature of 40-80° C., and crystallizing same to obtain a crude glucurolactone.
A method for producing D-glucuronic acid by means of biological fermentation and a method for preparing glucurolactone using glucuronic acid, which belong to the technical field of biological preparation. The methods comprise the following steps: culturing recombinant engineering bacteria to obtain a seed solution; inoculating the seed solution onto a fermentation tank culture medium for fermentation culture; obtaining a fermentation solution by means of feeding control and induction control; performing centrifugation or membrane filtration on the fermentation solution to obtain a wet thallus; and adding the wet thallus to a reaction solution for conversion to obtain D-glucuronic acid. Furthermore, adding the D-glucuronic acid solution to a concentrated phosphoric acid, performing an esterification reaction under stirring conditions at a reaction temperature of 40-80°C, and crystallizig same to obtain a crude glucurolactone. By using the fermentation process to produce D-glucuronic acid, the inositol conversion rate can reach 95% or above, the amount of obtained D-glucuronic acid is higher than 76 g/L, and the inositol oxidase can also be reused. The time from the reaction to the completion of crystallization is less than 6 hours. Therefore, the reaction and crystallization time is greatly shortened, the production cycle is shortened, and the production efficiency is improved.
The present invention relates to a stevioside M crystal form, a preparation method therefor and a use thereof, and specifically, relates to a naturally extracted high-intensity sweetener, i.e., a stevioside M crystal form A, the preparation method therefor and the user thereof. By means of comprehensive characterization of the new crystal form, the new crystal form is found to have advantages such as a high degree of crystallinity, good stability, and low hygroscopicity, and is applicable to a more comprehensive field of application. The preparation method in the present invention is simple and easy to operate, has high selectivity and good reproducibility, and can stably obtain the target crystal form.
Provided are crystalline form A of rebaudioside D, and a preparation method and application therefor. In X-ray powder diffraction analysis measured using Cu-Kα rays and with 2θ being expressed in degrees, crystalline form A of rebaudioside D has significant characteristic diffraction peaks at least at 4.53, 6.38, 12.76, 13.52, 17.48, 17.96, 20.07 and 22.63. The preparation method is a suspension method, a solvent evaporation method or a cooling method. The preparation method has a simple process, and is convenient to operate. A rebaudioside D crystalline form A product has a good degree of crystallinity, good water solubility, and high chemical stability.
A23L 33/00 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
C07H 15/26 - Radicaux acycliques ou carbocycliques substitués par des hétérocycles
A23L 2/02 - Boissons non alcooliséesCompositions sèches ou concentrés pour les fabriquer Leur préparation ou leur traitement contenant des jus de fruits ou de légumes
The present invention relates to the technical field of chemical drugs and crystal form processes, and to a pyrroloquinoline quinine B crystal form and a preparation method therefor. The present invention comprehensively characterizes the pyrroloquinoline quinine B crystal form by virtue of means such as X-ray powder diffraction analysis, thermo-gravimetric analysis, and differential scanning calorimetry analysis so as to find the fact that the pyrroloquinoline quinine B crystal form is high in crystallinity and low in hygroscopicity, and a regular crystal form can be formed, thereby facilitating process treatment and improvement of physical and chemical properties of a medicine, and improving the patent medicine performance. The preparation method for the pyrroloquinoline quinone B crystal form provided in the present invention is simple, easy to control, and high in reproducibility.
The present invention relates to a stevioside M crystal form, a preparation method therefor and a use thereof, and specifically, relates to a naturally extracted high-intensity sweetener, i.e., a stevioside M crystal form A, the preparation method therefor and the user thereof. By means of comprehensive characterization of the new crystal form, the new crystal form is found to have advantages such as a high degree of crystallinity, good stability, and low hygroscopicity, and is applicable to a more comprehensive field of application. The preparation method in the present invention is simple and easy to operate, has high selectivity and good reproducibility, and can stably obtain the target crystal form.
A23L 33/125 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sirops d'hydrate de carboneModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sucresModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des alcools de sucreModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des hydrolysats d'amidon
Preparations for making beverages; essences for making
flavored mineral water, not in the nature of essential oils;
preparations for making aerated water; powders for
effervescing beverages; non-alcoholic fruit extracts; waters
[beverages]; non-alcoholic beverages; cocktails,
non-alcoholic; fruit nectars, non-alcoholic; beer.
9.
CRYSTAL FORM OF REBAUDIOSIDE B AND PREPARATION PROCESS THEREFOR AND USE THEREOF
The present invention relates to a naturally-extracted high-sweetener stevioside, and in particular to a new crystal form of a rebaudioside B, and a preparation process therefor and a use thereof. The new crystal form is fully characterized by solid chemical analysis methods such as XRPD, DSC, TGA and DVS. It is found that the new crystal form has the advantages of high crystallinity, good stability, good water solubility and low hygroscopicity, and the crystal form is suitable for fields with extensive applications. The preparation method according to the present invention is simple and easily operable, features high selectivity and reproduciblity, and a target crystal form may be stably obtained.
C07H 1/00 - Procédés de préparation des dérivés du sucre
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A natural extract high-intensity sweetener steviol glycoside, specifically related to a novel steviol C-glycoside crystal, a preparation method for same, and applications thereof. The novel crystal has the advantages of high crystallinity, great stability, and low hygroscopicity and is suitable for a further broadened field of applications. The preparation method is simple and easy to operate, has increased selectivity and great reproducibility, and allows steady production of the target crystal.
C07H 1/00 - Procédés de préparation des dérivés du sucre
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 31/704 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p. ex. phloridzine liés à un système carbocyclique condensé, p. ex. sennosides, thiocolchicosides, escine, daunorubicine, digitoxine
The present invention relates to the naturally extracted high intensity sweetener stevioside, and specifically relates to a novel crystal form of steviolbioside, and a manufacturing method and application therefor. The novel crystal form has been comprehensively characterised by means of solid chemical analysis methods such as XRPD, DSC, TGA, and DVS, discovering that the novel crystal form has the advantages of high crystallinity, good stability, and low hygroscopicity, and is therefore suitable for use in a wide range of fields. The manufacturing method disclosed in the present invention is simple and easy to operate, has high selectivity and good reproducibility, and can stably obtain the target crystal form.
C07H 1/00 - Procédés de préparation des dérivés du sucre
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
The present invention relates to a naturally-extracted high potency sweetener rebaudioside, and particularly relates to a novel crystal form of a sodium salt of rebaudioside B and a preparation method thereof. The novel crystal form is comprehensively characterized using means of solid chemical analysis such as XRD, DSC, TGA, DVS, and the like, with the finding that the novel crystal form has the characteristics of a high crystallinity, stable physico-chemical properties, good water solubility, low hygroscopicity, and high flowability. The novel crystal form therefore has superior physico-chemical properties and is suitable for a wider range of applications. A preparation method of a novel crystal form A of the sodium salt of rebaudioside B is simple, easily controlled, and reproducible to provide a steady supply of the target crystal form.
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
The present invention provides a baicalein caffeine eutectic crystal, a preparation method therefor, a pharmaceutical composition, and application thereof. The baicalein caffeine eutectic crystal of the present invention has an excellent dissolution rate and bioavailability. The preparation method for the baicalein caffeine eutectic crystal provided in the present invention is simple, easy to control, and high in reproducibility, and can obtain a target eutectic crystal stably.
C07D 311/30 - Benzo [b] pyrannes non hydrogénés dans le carbocycle avec des atomes d'oxygène ou de soufre liés directement en position 4 avec des cycles aromatiques liés en position 2 ou 3 avec des cycles aromatiques liés uniquement en position 2 non hydrogénés dans l'hétérocycle, p. ex. flavones
C07D 473/12 - Composés hétérocycliques contenant des systèmes cycliques purine avec des atomes d'oxygène, de soufre ou d'azote liés directement en positions 2 et 6 deux atomes d'oxygène avec des radicaux contenant uniquement des atomes d'hydrogène et de carbone, liés en position 1 ou 3 avec des radicaux méthyle en positions 1, 3 et 7, p. ex. caféine
A61K 31/522 - Purines, p. ex. adénine ayant des groupes oxo liés directement à l'hétérocycle, p. ex. hypoxanthine, guanine, acyclovir
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
The present invention relates to the technical field of chemical drugs and crystal form processes, and to a pyrroloquinoline quinone B crystal form and a preparation method therefor. The present invention comprehensively characterizes the pyrroloquinoline quinone B crystal form by virtue of means such as X-ray powder diffraction analysis, thermo-gravimetric analysis, and differential scanning calorimetry analysis so as to find the fact that the pyrroloquinoline quinone B crystal form is high in crystallinity and low in hygroscopicity, and a regular crystal form can be formed, thereby facilitating process treatment and improvement of physical and chemical properties of a medicine, and improving the patent medicine performance. The preparation method for the pyrroloquinoline quinone B crystal form provided in the present invention is simple, easy to control, and high in reproducibility.
Provided are crystalline form A of rebaudioside D, and a preparation method and application therefor. In X-ray powder diffraction analysis measured using Cu-Kα rays and with 2θ being expressed in degrees, crystalline form A of rebaudioside D has significant characteristic diffraction peaks at least at 4.53, 6.38, 12.76, 13.52, 17.48, 17.96, 20.07 and 22.63. The preparation method is a suspension method, a solvent evaporation method or a cooling method. The preparation method has a simple process, and is convenient to operate. A rebaudioside D crystalline form A product has a good degree of crystallinity, good water solubility, and high chemical stability.
C07H 15/26 - Radicaux acycliques ou carbocycliques substitués par des hétérocycles
A23L 19/00 - Produits à base de fruits ou de légumesLeur préparation ou leur traitement
A23L 2/02 - Boissons non alcooliséesCompositions sèches ou concentrés pour les fabriquer Leur préparation ou leur traitement contenant des jus de fruits ou de légumes
A23L 33/00 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement
A61K 31/4402 - Pyridines non condenséesLeurs dérivés hydrogénés substituées uniquement en position 2, p. ex. phéniramine, bisacodyl
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
The present invention relates to the technical field of pharmaceutical chemistry, especially to Baicalin crystal form A, and preparation method and application thereof. The crystal form shows characteristic peaks at X-ray powder diffraction angles, represented by 2θ, of 4.99, 5.65, 6.99, 8.21, 8.64, 9.95, 11.78, 11.98, 12.61, 14.94, 16.33, 17.38, 18.52, 20.76, 21.26, 21.68, 24.94, 26.64, 28.80, and 29.97 degrees. A preparation method for the crystal form comprises the following steps: dissolving a double salt precipitate, acid-precipitation, and recrystallization. The preparation method is easily implemented. The present invention has reduced hygroscopicity of the crystal form and excellent stability, and a regular crystal morphology can be formed, thereby facilitating improvements in medicine fabricating process and physicochemical properties, so as to enhance drug performance.
A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p. ex. leucoglucosane, hespéridine, érythromycine, nystatine
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
05 - Produits pharmaceutiques, vétérinaires et hygièniques
30 - Aliments de base, thé, café, pâtisseries et confiseries
Produits et services
Medicines for human purposes; dietetic substances adapted for medical use; Dietetic beverages adapted for medical purposes; Nutritional supplements; Powdered milk for babies; Medicinal herbs; Dietetic foods adapted for medical purposes; Protein dietary supplements; Tonics [medicines]; Disinfectants for hygiene purposes. Sauces [condiments]; food flavorings, other than essential oils; flavorings [flavourings], other than essential oils, for beverages; dressings for salad; hot pepper powder [spice]; Vanilla [flavoring] [flavouring]; gluten additives for culinary purposes; condiments; seasonings; spices.
18.
Crystalline forms of pyrroloquinoline quinone disodium salt
The present invention relates to crystalline forms of pyrroloquinoline quinone disodium salt. The present invention provides crystalline Form A and crystalline Form B of pyrroloquinoline quinone disodium salt, and the methods and uses for the preparation thereof. The X-ray powder diffraction patterns of crystalline Form A and crystalline Form B are as shown by FIG. 1 and FIG. 5, respectively. The crystalline forms of the present invention have low moisture absorption and high stability, as well as excellent use and storage performances.
Disclosed is a stevioside A glycoside crystal form 9, of which the structure is represented by the formula I. The X-ray powder derivative (XRPD) figure of the crystal form 9 has the following characteristic peaks at the angles of 2θ±0.1 degrees: 4.748, 9.511, 11.767, 13.598, 14.038, 17.224, 19.242, and 23.428.
A23L 1/221 - Epices, agents aromatiques ou condiments naturels; Leurs extraits
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
20.
STEVIOSIDE A GLYCOSIDE CRYSTAL, PREPARATION METHOD THEREFOR, AND USES THEREOF
Disclosed is a stevioside A glycoside crystal form 7, the structure whereof is represented by the formula I. The X-ray powder diffraction (XRPD) figure of the crystal form 7 has the following characteristic peaks at the angles of 2θ±0.1 degrees: 4.80, 5.48, 8.42, 9.27, 11.06, 11.27, 11.86, 12.62, 13.59, 14.20, 15.07, 15.44, 17.05, 17.72, 18.13, 18.62, 19.36, 21.26, 21.95, 22.75, 23.59, 24.14, 24.73, 25.01, 25.54, 25.98, and 26.56.
A23L 29/30 - Aliments ou produits alimentaires contenant des additifsLeur préparation ou leur traitement contenant des sirops d'hydrate de carboneAliments ou produits alimentaires contenant des additifsLeur préparation ou leur traitement contenant des sucresAliments ou produits alimentaires contenant des additifsLeur préparation ou leur traitement contenant des alcools de sucre, p. ex. du xylitolAliments ou produits alimentaires contenant des additifsLeur préparation ou leur traitement contenant des hydrolysats d'amidon, p. ex. de la dextrine
Disclosed are an inositol crystal, preparation method therefor and use thereof. The X-ray powder diffraction (XRPD) pattern of crystal form C has characteristic peaks at the following angles of 2θ±0.2°： 14.86°, 17.82°, 20.38°, 25.32°, 26.42°, 28.39°, 31.28° and 34.33°.
Provided are pyrroloquinoline quinone disodium salt crystals A and B, and the preparation method and use thereof. The crystal has low moisture absorption and high stability, as well as excellent use and storage performances.
A61K 31/4745 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. phénanthrolines
